Insider Transactions in Q1 2022 at Inovio Pharmaceuticals, Inc. (INO)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2022
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,247
-8.65%
|
$21,741
$3.63 P/Share
|
|
Mar 25
2022
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+16.59%
|
-
|
|
Mar 21
2022
|
Ann Calby Miller Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,273
+12.64%
|
-
|
|
Mar 16
2022
|
Simon X Benito Director |
SELL
Open market or private sale
|
Direct |
2,000
-3.37%
|
$6,000
$3.16 P/Share
|
|
Mar 16
2022
|
Simon X Benito Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+3.26%
|
$4,000
$2.2 P/Share
|
|
Mar 14
2022
|
David B. Weiner Director |
SELL
Open market or private sale
|
Direct |
4,083
-0.46%
|
$12,249
$3.2 P/Share
|
|
Mar 11
2022
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,410
-14.91%
|
$94,230
$3.22 P/Share
|
|
Mar 11
2022
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,737
+22.09%
|
-
|
|
Mar 11
2022
|
Jong Joseph Kim Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,698
-2.71%
|
$119,094
$3.22 P/Share
|
|
Mar 11
2022
|
Jong Joseph Kim Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
139,387
+8.7%
|
-
|
|
Mar 11
2022
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,667
+1.3%
|
-
|
|
Mar 11
2022
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,974
-27.9%
|
$77,922
$3.22 P/Share
|
|
Mar 11
2022
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,737
+39.08%
|
-
|
|
Mar 11
2022
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,316
-13.3%
|
$123,948
$3.22 P/Share
|
|
Mar 11
2022
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
119,474
+27.77%
|
-
|
|
Mar 09
2022
|
David B. Weiner Director |
SELL
Open market or private sale
|
Direct |
4,083
-0.46%
|
$12,249
$3.33 P/Share
|
|
Mar 08
2022
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,666
+1.31%
|
-
|
|
Mar 08
2022
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,882
-6.72%
|
$20,646
$3.26 P/Share
|
|
Mar 08
2022
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,900
+16.26%
|
-
|
|
Mar 08
2022
|
Jong Joseph Kim Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,142
-1.35%
|
$54,426
$3.26 P/Share
|
|
Mar 08
2022
|
Jong Joseph Kim Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,700
+4.53%
|
-
|
|
Mar 08
2022
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,287
-6.96%
|
$33,861
$3.26 P/Share
|
|
Mar 08
2022
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,466
+11.68%
|
-
|
|
Feb 26
2022
|
Jong Joseph Kim Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,045
-1.55%
|
$60,135
$3.22 P/Share
|
|
Feb 26
2022
|
Jong Joseph Kim Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,767
+5.03%
|
-
|
|
Feb 26
2022
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,764
-24.39%
|
$32,292
$3.22 P/Share
|
|
Feb 26
2022
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,545
+33.81%
|
-
|
|
Feb 26
2022
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,545
-9.38%
|
$25,635
$3.22 P/Share
|
|
Feb 26
2022
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,545
+19.83%
|
-
|
|
Feb 26
2022
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,555
-8.19%
|
$37,665
$3.22 P/Share
|
|
Feb 26
2022
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,545
+12.82%
|
-
|
|
Feb 26
2022
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,667
+1.33%
|
-
|
|
Jan 19
2022
|
Simon X Benito Director |
SELL
Open market or private sale
|
Direct |
2,000
-3.37%
|
$8,000
$4.27 P/Share
|
|
Jan 19
2022
|
Simon X Benito Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+3.26%
|
$4,000
$2.2 P/Share
|
|
Jan 15
2022
|
Jay Shepard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,274
+19.86%
|
-
|
|
Jan 05
2022
|
Lota S. Zoth Director |
SELL
Open market or private sale
|
Direct |
961
-3.7%
|
$4,805
$5.01 P/Share
|
|
Jan 03
2022
|
Lota S. Zoth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,090
+13.6%
|
-
|